NASDAQ · ANNXHealthcarePharmaceuticals

Annexon financials

$4.13+2.99%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
FY22
Dec 31
FY21
Dec 31
FY20
Dec 31
Revenue$0.00$0.00$0.00$0.00——
Gross profit$0.00$0.00$0.00$0.00——
Gross margin——————
Operating income-$216.4M-$154.1M-$143.7M-$145.6M-$130.7M-$63.5M
Net income-$208.5M-$138.2M-$134.2M-$141.9M-$130.3M-$70.3M
Net margin——————
Diluted EPS$-1.34$-1.01$-1.77$-2.60$-3.40$-4.15
EBITDA-$214.2M-$151.9M-$141.6M-$142.3M-$127.3M-$62.8M
Operating cash flow-$186.4M-$118.0M-$121.1M-$116.3M-$106.1M-$53.1M
Free cash flow-$186.5M-$118.0M-$121.3M-$122.8M-$107.8M-$53.6M
Diluted shares155.1M137.4M75.7M54.7M38.3M17.0M

Balance sheet

Period endDec 31Dec 31Dec 31Dec 31Dec 31Dec 31
Cash & equivalents$162.1M$49.5M$225.1M$140.0M$74.8M$268.6M
Short-term investments$76.3M$262.5M$34.6M$102.6M$167.9M$82.6M
Total debt$0.00$0.00$0.00$0.00$0.00$0.00
Total assets$277.6M$350.1M$297.7M$285.1M$287.0M$355.9M
Total liabilities$65.9M$57.0M$47.1M$53.9M$55.1M$11.7M
Shareholders' equity$211.6M$293.1M$250.6M$231.2M$231.9M$344.3M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology